Jefferson Michael Jones1,2,3, Lori R Armstrong1. 1. 1 Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2. 2 The CDC Experience Applied Epidemiology Fellowship, Scientific Education and Professional Development Program Office, Centers for Disease Control and Prevention, Atlanta, GA, USA. 3. 3 National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
OBJECTIVES: Drug-susceptibility testing (DST) of Mycobacterium tuberculosis is necessary for identifying drug-resistant tuberculosis, administering effective treatment regimens, and preventing the spread of drug-resistant tuberculosis. DST is recommended for all culture-confirmed cases of tuberculosis. We examined trends in delayed and unreported DST results in the Centers for Disease Control and Prevention's National Tuberculosis Surveillance System. METHODS: We analyzed culture-confirmed tuberculosis cases reported to the National Tuberculosis Surveillance System during 1993-2014 for annual trends in initial DST reporting for first-line antituberculosis drugs and trends in on-time, delayed, and unreported results. We defined on-time reporting as DST results received during the same calendar year in which the patient's case was reported or ≤4 months after the calendar year ended and delayed reporting as DST results received after the calendar year. We compared cases with on-time, delayed, and unreported DST results by patient and tuberculosis program characteristics. RESULTS: The proportion of cases with reported results for all first-line antituberculosis drugs increased during 1993-2011. Reporting of pyrazinamide results was lower than reporting of other drugs. However, during 2000-2012, of 134 787 tuberculosis cases reported to the National Tuberculosis Surveillance System, reporting was on time for 125 855 (93.4%) cases, delayed for 5332 (4.0%) cases, and unreported for 3600 (2.7%) cases. CONCLUSIONS: Despite increases in the proportion of cases with on-time DST results, delayed and unreported results persisted. Carefully assessing causes for delayed and unreported DST results should lead to more timely reporting of drug-resistant tuberculosis.
OBJECTIVES: Drug-susceptibility testing (DST) of Mycobacterium tuberculosis is necessary for identifying drug-resistant tuberculosis, administering effective treatment regimens, and preventing the spread of drug-resistant tuberculosis. DST is recommended for all culture-confirmed cases of tuberculosis. We examined trends in delayed and unreported DST results in the Centers for Disease Control and Prevention's National Tuberculosis Surveillance System. METHODS: We analyzed culture-confirmed tuberculosis cases reported to the National Tuberculosis Surveillance System during 1993-2014 for annual trends in initial DST reporting for first-line antituberculosis drugs and trends in on-time, delayed, and unreported results. We defined on-time reporting as DST results received during the same calendar year in which the patient's case was reported or ≤4 months after the calendar year ended and delayed reporting as DST results received after the calendar year. We compared cases with on-time, delayed, and unreported DST results by patient and tuberculosis program characteristics. RESULTS: The proportion of cases with reported results for all first-line antituberculosis drugs increased during 1993-2011. Reporting of pyrazinamide results was lower than reporting of other drugs. However, during 2000-2012, of 134 787 tuberculosis cases reported to the National Tuberculosis Surveillance System, reporting was on time for 125 855 (93.4%) cases, delayed for 5332 (4.0%) cases, and unreported for 3600 (2.7%) cases. CONCLUSIONS: Despite increases in the proportion of cases with on-time DST results, delayed and unreported results persisted. Carefully assessing causes for delayed and unreported DST results should lead to more timely reporting of drug-resistant tuberculosis.
Authors: Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon Journal: Am J Respir Crit Care Med Date: 2003-02-15 Impact factor: 21.405
Authors: M Lagrange-Xélot; R Porcher; S Gallien; A Wargnier; J Pavie; N de Castro; J-M Molina Journal: Clin Microbiol Infect Date: 2011-04 Impact factor: 8.067
Authors: Karen B DeSalvo; Patrick W O'Carroll; Denise Koo; John M Auerbach; Judith A Monroe Journal: Am J Public Health Date: 2016-04 Impact factor: 9.308
Authors: Frances C Tyrrell; Gary E Budnick; Thor Elliott; Laura Gillim-Ross; Mary V Hildred; Peggy Mahlmeister; Nicole Parrish; Michael Pentella; Jolene Vanneste; Yun F Wayne Wang; Angela M Starks Journal: J Clin Microbiol Date: 2012-07-25 Impact factor: 5.948
Authors: Ryan Maclaren Wallace; J Steve Kammerer; Michael F Iademarco; Sandy P Althomsons; Carla A Winston; Thomas R Navin Journal: Am J Respir Crit Care Med Date: 2009-08-13 Impact factor: 21.405
Authors: Suzanne M Marks; Jennifer Flood; Barbara Seaworth; Yael Hirsch-Moverman; Lori Armstrong; Sundari Mase; Katya Salcedo; Peter Oh; Edward A Graviss; Paul W Colson; Lisa Armitige; Manuel Revuelta; Kathryn Sheeran Journal: Emerg Infect Dis Date: 2014-05 Impact factor: 6.883